Cyclosporine
Immune / TransplantAlso known as: Sandimmune, Neoral, Restasis, Cyclosporin A
Mechanism
A powerful immunosuppressive drug originally derived from a soil fungus, used to prevent organ transplant rejection and treat severe autoimmune diseases. It works by blocking T-cell activation — the key immune cells responsible for attacking transplanted organs. Also available as eye drops (Restasis) for chronic dry eye. Revolutionized organ transplantation when introduced in the 1980s.
Technical detail
Cyclic undecapeptide (11 amino acids, 7 N-methylated) isolated from Tolypocladium inflatum fungus. MW 1202 Da. Mechanism: binds cyclophilin A (CypA, an immunophilin) forming cyclosporine-CypA complex that inhibits calcineurin (calcium/calmodulin-dependent serine-threonine phosphatase). Calcineurin normally dephosphorylates NFAT (nuclear factor of activated T-cells), allowing nuclear translocation and IL-2 transcription. Cyclosporine blocks this pathway, suppressing IL-2 production, T-cell proliferation, and helper/cytotoxic T-cell activation. Oral bioavailability: 10-89% (Sandimmune) vs 20-50% more consistent (Neoral microemulsion). Metabolized by CYP3A4 and P-glycoprotein (numerous drug interactions). Target trough levels: 150-300 ng/mL (transplant), 100-200 ng/mL (autoimmune). Nephrotoxicity (dose-limiting): afferent arteriolar vasoconstriction and chronic tubulointerstitial fibrosis. Other toxicities: hypertension, tremor, gingival hyperplasia, hirsutism. Restasis (0.05% ophthalmic emulsion): local immunomodulation for dry eye.
Effects
**Immune System (Tier 1 — FDA-approved, Foundational Immunosuppressant):** Cyclosporine (cyclosporin A) is a cyclic undecapeptide (11 amino acids) derived from the fungus Tolypocladium inflatum. It revolutionized organ transplantation when introduced in the 1980s. Mechanism: cyclosporine binds to cyclophilin (an intracellular immunophilin), and the cyclosporine-cyclophilin complex inhibits calcineurin — a calcium/calmodulin-dependent serine-threonine phosphatase. Calcineurin normally dephosphorylates NFAT (nuclear factor of activated T-cells), allowing it to translocate to the nucleus and activate IL-2 and other cytokine gene transcription. By blocking calcineurin, cyclosporine specifically suppresses T-cell activation and IL-2 production without killing the cells. **Transplant Immunology (Tier 1):** Prevents acute organ rejection in kidney, liver, heart, lung, and bone marrow transplantation. Suppresses the alloreactive T-cell response that drives graft rejection. Used as part of multi-drug immunosuppressive regimens (typically with mycophenolate and corticosteroids). Transformed transplant medicine: 1-year graft survival improved from ~50% to >80% when cyclosporine was introduced. **Autoimmune/Inflammatory (Tier 1):** FDA-approved for: rheumatoid arthritis (severe, refractory), psoriasis (severe), nephrotic syndrome, and dry eye disease (Restasis ophthalmic emulsion). Used off-label for: atopic dermatitis, ulcerative colitis, lupus nephritis, myasthenia gravis, and many other autoimmune conditions. **Renal System (Tier 1 — Adverse Effect):** Nephrotoxicity is the most significant dose-limiting toxicity. Cyclosporine causes afferent arteriolar vasoconstriction → reduced renal blood flow → decreased GFR. Acute nephrotoxicity is dose-dependent and reversible. Chronic nephrotoxicity causes irreversible interstitial fibrosis and tubular atrophy. Up to 20-30% of transplant patients develop chronic cyclosporine nephropathy over 10+ years. **Cardiovascular/Metabolic (Tier 1 — Adverse Effects):** Hypertension (occurs in 25-50% of patients — due to renal vasoconstriction and sodium retention), hyperlipidemia, hyperkalemia, hypomagnesemia, hyperuricemia/gout. Increased cardiovascular risk with long-term use. **Neurological (Tier 2 — Adverse Effects):** Tremor (common), headache, paresthesias. Rare but serious: posterior reversible encephalopathy syndrome (PRES), seizures.
Practitioner Guide
**Transplant Immunosuppression:** - Initial dose: 10-15mg/kg/day divided BID, starting 4-12 hours pre-transplant - Maintenance: 5-10mg/kg/day divided BID, adjusted to trough levels - Target trough levels: vary by organ, time post-transplant, and center protocol - Kidney: 150-300 ng/mL (months 0-3), 100-200 ng/mL (months 3-12), 75-150 ng/mL (after year 1) - Heart/Liver: similar ranges, center-specific - Available formulations: Sandimmune (original) vs. Neoral/Gengraf (modified/microemulsion — BETTER and MORE CONSISTENT absorption) - CRITICAL: Sandimmune and Neoral are NOT bioequivalent — do not interchange without dose adjustment **Autoimmune Disease Use:** - Psoriasis: 2.5-5mg/kg/day divided BID; response in 4-8 weeks; limit to 1-2 year courses due to nephrotoxicity - Rheumatoid arthritis: 2.5-4mg/kg/day divided BID; often combined with methotrexate - Atopic dermatitis (off-label): 3-5mg/kg/day for flare management; bridge to steroid-sparing agents - Ulcerative colitis (severe/steroid-refractory): 2-4mg/kg/day IV (rescue therapy to avoid colectomy) **Essential Monitoring:** - Cyclosporine trough levels: every 2-4 weeks initially, monthly once stable - Renal function: serum creatinine and BUN at every visit (minimum monthly) - Blood pressure: at every visit; treat hypertension aggressively (amlodipine preferred — nifedipine is alternative; avoid diltiazem/verapamil which increase cyclosporine levels) - Electrolytes: potassium (hyperkalemia risk), magnesium (hypomagnesemia common — supplement) - Lipid panel: every 3-6 months - CBC: periodic monitoring **Critical Drug Interactions:** - CYP3A4 inhibitors INCREASE cyclosporine levels (toxicity risk): azole antifungals (ketoconazole, fluconazole), macrolide antibiotics (erythromycin, clarithromycin), calcium channel blockers (diltiazem, verapamil), grapefruit juice - CYP3A4 inducers DECREASE cyclosporine levels (rejection risk): rifampin, phenytoin, carbamazepine, St. John's wort - Nephrotoxic drugs: AVOID combining with NSAIDs, aminoglycosides, amphotericin B — additive nephrotoxicity - Statins: increased risk of rhabdomyolysis — use lowest statin dose, avoid simvastatin
Research Summary
**Tier 1 — Foundational Immunosuppressant, Decades of Data:** - Discovered 1971 (Sandoz), FDA approved 1983 (Sandimmune), reformulated 1995 (Neoral) - Revolutionized transplant medicine: Nobel Prize-level impact on the field - Thousands of clinical trials across transplantation and autoimmune disease - Restasis (cyclosporine 0.05% ophthalmic): FDA approved 2003 for dry eye disease - Long-term safety data: >40 years of post-market surveillance **Tier 2 — Established Clinical Evidence:** - Comparison to tacrolimus (FK506): multiple RCTs showing tacrolimus is more potent but similar safety profile; tacrolimus has largely replaced cyclosporine as first-line in many transplant programs - Cyclosporine in dermatology: extensive evidence in psoriasis, atopic dermatitis, pyoderma gangrenosum, chronic urticaria - Biomarker-guided dosing: C2 monitoring (2-hour post-dose level) may be superior to trough monitoring for some indications **Tier 3 — Emerging/Novel Applications:** - Cyclosporine in COVID-19: calcineurin inhibition may reduce cytokine storm; observational data in transplant patients suggests cyclosporine users did not have worse COVID outcomes (possibly better) - Topical/local cyclosporine: dermal formulations for localized autoimmune skin conditions - Cyclosporine analogs without immunosuppressive activity: cyclophilin inhibitors for hepatitis C (alisporivir) and neurodegenerative disease (mitochondrial permeability transition pore inhibition)